Q&A with Brigham Principal Investigator and Hematologist/Oncologist Ann Mullally
Ann Mullally, MD, is a physician-scientist who sees patients at Dana-Farber Cancer Institute and runs a research laboratory based at BWH. The Mullally lab in the BWH Division of Hematology is investigating the biology and treatment of myeloid malignancies, diseases…
Ann Mullally receives Clinical Investigator Continuation Grant
Ann Mullally, MD, a physician-scientist in the Division of Hematology, was awarded a Clinical Investigator Continuation Grant from the Damon Runyon Cancer Research Foundation for her project, “Peptide Vaccination to Target Mutant Calreticulin in Myeloproliferative Neoplasms (MPN).” The award, which provides…
Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation
Our paper "Mutant Calreticulin Requires Both its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation" gets published in Cancer Discovery!
